This month’s news on new hires, board launches, acquisitions, and other important news includes items on Pfizer, Javara, Clinical Ink, and other companies.
The acquisition of two migraine therapies from Dr Reddy’s has been completed by Upsher-Smith, adding different drug delivery treatment options to its migraine product portfolio.
Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
WCG acquires Analgesic Solutions for advisement on protocol design and the development of clinical trials in which pain is an indicator of an underlying condition.
C2 Pharma acquires digoxin API product portfolio from Noblius to secure supply of the ingredient, after disruption of the supply of the API for a number of years.
The institutional review board industry sees further consolidation as Advarra acquires Quorum and its research and technology consulting division, Kinetiq.
The PE firm Ampersand Capital Partners has acquired Pacific Biomarkers and is merging the CRO with Neomed-Labs to streamline clinical immunology development.
InvVax’s universal flu vaccine candidate has demonstrated preclinical success as the company prepares for a Phase I clinical trial, supported by a Series A fundraising round.
Takeda is in talks to sell Shire’s experimental inflammatory bowel disease pipeline in an effort to meet European regulators approval for the acquisition.
Velesco Pharma has expanded its analytical research and development capabilities to meet a growing demand for its services after acquiring a new facility in Michigan.
BioIVT will use its new internal cloud-based Quality Management System to manage clinical trial data at all of its locations, following the acquisition of five companies since 2017.
An additional investment at the PCI clinical services’ site brought forth an expansion to support the return of investigational drug products used in clinical trials.
DZS Clinical Services has been acquired by the global CRO WDMD in a deal that will expand its service offerings globally with the addition of coverage in Europe and Japan.
The Nuvisan Group is taking on part of Galderma’s R&D capacities site, growing its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics
